Progenity to Present Key Prospective Verification Study Data for its Preeclampsia Rule-Out Test at 2021 American College of Obstetricians and Gynecologists Annual Meeting

Rhea-AI Summary

Progenity, Inc. (Nasdaq: PROG) will present verification study data for its Preecludia™ rule-out test for preeclampsia at the ACOG Annual Clinical and Scientific Meeting from April 30 – May 2, 2021. The presentation, titled Performance of a novel multi-biomarker rule out preeclampsia test: a prospective verification study, will include contributions from noted authors such as Matthew Cooper, PhD. The virtual meeting will feature interactive ePosters, with the poster number being 999251. Details will be accessible on the Progenity website post-conference.

SAN DIEGO, April 08, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products in women’s health, will be presenting verification study data for its Preecludia™ rule-out test for preeclampsia at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting set to take place April 30 – May 2, 2021.

The data presented will be a part of the virtual meeting’s interactive ePosters. Details of the presentation are as follows:

Title – Performance of a novel multi-biomarker rule out preeclampsia test: a prospective verification study
Authors – Matthew Cooper, PhD, DABT, MBA; Amin Mazloom, PhD; Chelsea Obrochta, PhD(c); Ronald Wapner, MD; Todd Rosen, MD; Allan Bombard, MD
Poster number 999251

ACOG anticipates publishing abstracts and posters the week of April 26^th. The poster presentation will also be made available on the Progenity website following the conference.

ABOUT PROGENITY, INC.
Progenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine. Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. The company applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.

For more information about Progenity’s products and pipeline visit www.progenity.com, or follow the company on LinkedIn or Twitter.

Investor Contact:
Robert Uhl
Managing Director, Westwicke ICR
ir@progenity.com
(619) 228-5886

Progenity Media Contact:
Angela Salerno-Robin
dna Communications
ASalerno-Robin@dna-comms.com  
(212) 445-8219 

FAQ

What is the Preecludia™ test by Progenity?

Preecludia™ is a rule-out test for preeclampsia that utilizes a multi-biomarker approach.

When will Progenity present its data at ACOG?

Progenity will present data from April 30 to May 2, 2021, at the ACOG Annual Clinical and Scientific Meeting.

Who authored the presentation on the Preecludia™ test?

The presentation was authored by Matthew Cooper, PhD, and other experts in the field.

What is the significance of the verification study data?

The verification study data aims to validate the performance of the Preecludia™ test for clinical use in diagnosing preeclampsia.

Where can I find the poster presentation after the conference?

The poster presentation will be available on the Progenity website following the ACOG conference.